Patents Assigned to Dana-Farber Cancer Institute, Inc.
  • COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL STORAGE DISEASES AND DISORDERS
    Publication number: 20190367584
    Abstract: The present invention provides compositions and methods for the treatment or prevention of a lysosomal disease or disorder involving increasing the level, expression, or activity of a metallothionein polypeptide or polynucleotide in the subject.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 5, 2019
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: ALESSANDRA BIFFI, ELEONORA CAVALCA
  • REGULATING CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20190365875
    Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.
    Type: Application
    Filed: February 8, 2018
    Publication date: December 5, 2019
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: James Bradner, Justin Roberts, Behnam Nabet, Georg Winter, Andrew J. Phillips, Timothy P. Heffernan, Dennis Buckley
  • IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF
    Publication number: 20190367487
    Abstract: The present disclosure provides imidazolyl compounds of Formula (I) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: May 13, 2019
    Publication date: December 5, 2019
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Hwan Geun Choi, Yanke Liang
  • DISSOCIATION OF HUMAN TUMOR TO SINGLE CELL SUSPENSION FOLLOWED BY BIOLOGICAL ANALYSIS
    Publication number: 20190367964
    Abstract: Described herein are compositions and methods of disaggregating a tissue sample into single cells.
    Type: Application
    Filed: February 2, 2017
    Publication date: December 5, 2019
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Benjamin Izar, Levi Garraway, Asaf Rotem, Aviv Regev, Alexander Shalek, Marc Wadsworth, Sanjay Prakadan, Orit Rozenblatt-Rosen, Itay Tirosh
  • Stabilized insulinotropic peptides and methods of use
    Patent number: 10487129
    Abstract: The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: November 26, 2019
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Loren D. Walensky, Gregory Bird
  • USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS
    Publication number: 20190343842
    Abstract: The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate STK inhibitors of Formula (III)).
    Type: Application
    Filed: April 19, 2019
    Publication date: November 14, 2019
    Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Alykhan Shamji, Thomas Sundberg, Nathanael S. Gray, Ramnik Xavier, Stuart L. Schreiber, Hwan Geun Choi, Yanke Liang
  • Microfluidic cell culture of patient-derived tumor cell spheroids
    Patent number: 10472599
    Abstract: Provided herein are methods for culturing patient-derived tumor cell spheroids in a three-dimensional microfluidic device. The method comprises mincing primary tumor sample in a medium supplemented with serum; treating the minced primary tumor sample with a composition comprising an enzyme; collecting tumor spheroids having a diameter of 10 ?m to 500 ?m from the enzyme treated sample; suspending the tumor spheroids in biocompatible gel; and culturing the tumor spheroids in a three dimensional microfluidic device. Methods for identifying an agent for treating cancer and microfluidic devices that allow for the simultaneous exposure of the cultured patient-derived primary tumor cell spheroids to a treatment of choice and to control treatment are also provided.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: November 12, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: David Barbie, Amir Aref, Thanh Barbie, Russell W. Jenkins, Kwok-kin Wong
  • Antibody molecules to TIM-3 and uses thereof
    Patent number: 10472419
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 12, 2019
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma
    Patent number: 10465247
    Abstract: Diagnostic assays for facilitating the diagnosis of lymphoplasmacytic lymphoma (LPL) are provided. The method comprises assessing a biological sample of the subject for the presence of a mutation at position 38182641 in chromosome 3p22.2, wherein presence of the mutation is indicative that the subject has LPL. Also, provided are targeted therapies, methods for monitoring the progression or recurrence of LPL, and a sensitive and inexpensive real-time allele specific polymerase chain reaction assay for reliable and quantitative assessments of the mutation.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: November 5, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventor: Steven P. Treon
  • Stabilized anti-microbial peptides
    Patent number: 10464975
    Abstract: The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: November 5, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Rida Mourtada, Gregory H. Bird
  • Methods to induce targeted protein degradation through bifunctional molecules
    Patent number: 10464925
    Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: November 5, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Dennis Buckley, Georg Winter
  • Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
    Patent number: 10463732
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: November 5, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Chen Xu, De-Kuan Chang
  • Thiazolyl-containing compounds for treating proliferative diseases
    Patent number: 10464949
    Abstract: The present disclosure provides thiazolyl-containing compounds of Formula (I), (II), or (III). The compounds described herein may be able to inhibit protein kinases (e.g., Src family kinases (e.g., hemopoietic cell kinase (HCK)), Bruton's tyrosine kinase (BTK)) and may be useful in treating and/or preventing proliferative diseases (e.g., myelodysplasia, leukemia, lymphoma (e.g., Waldenström's macroglobulinemia)) and in inducing apoptosis in a cell (e.g., malignant blood cell). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: November 5, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Sara Jean Buhrlage, Steven P. Treon, Hwan Geun Choi, Yuan Xiong, Guang Yang
  • Compounds and methods for treating cancer
    Patent number: 10464897
    Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hh signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 5, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Michael Erb, Jun Qi
  • Agents that modulate immune cell activation and methods of use thereof
    Patent number: 10457733
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: October 29, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • Macrocyclic kinase inhibitors and uses thereof
    Patent number: 10457691
    Abstract: The present disclosure provides macrocyclic compounds of Formula (I). The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 29, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Hwan Geun Choi, Yanke Liang
  • Pyrimido-diazepinone compounds and methods of treating disorders
    Patent number: 10457692
    Abstract: The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 29, 2019
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, David Waller, Hwan Guen Choi, Jinhua Wang, Xianming Deng
  • Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
    Patent number: 10456465
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 29, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Bifunctional molecules for degradation of EGFR and methods of use
    Patent number: 10450310
    Abstract: The present application provides bifunctional compounds of Formula (I): which act as protein degradation inducing moieties for EGFR and/or a mutant thereof. The present application also describes methods for the targeted degradation of EGFR and/or a mutant thereof through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to EGFR and/or a mutant thereof which can be utilized in the treatment of disorders modulated by EGFR or a mutant thereof.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 22, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Jaebong Jang, Dries De Clercq, Michael Eck, Pasi Janne
  • Compositions and methods for sensitizing a neoplastic cell to radiation
    Patent number: 10449199
    Abstract: The invention provides for the use of radiation sensitizing agents in combination with radiation for the treatment of neoplasia, methods for the identification of genotype-specific radiation sensitizing agents, and methods of identifying patients who could benefit from therapy with a genotype-specific radiation sensitizing agent.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: October 22, 2019
    Assignees: THE BROAD INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Mohamed Abazeed, Matthew Meyerson, Drew Adams